XDx Announces Appointment of Vikram Jog as CFO
South San Francisco, May 2, 2005 - XDx, Inc., a molecular diagnostics company, today
announced the appointment of Vikram Jog to the position of chief financial officer (CFO).
In this newly established position, Jog will leverage his significant executive-level finance and
management experience to oversee the companyís financial functions and to help the
company achieve its financial goals, following the launch of its first offering — AlloMapTM
molecular expression testing for heart transplant patient management.
"Vikram has a wealth of industry experience and well-developed relationships, both within
the industry and the financial community, making him a great asset to XDx," said Pierre
Cassigneul, president and chief executive officer of XDx. "We are confident that Vikramís
appointment will have a positive impact on the future of this company, helping to position
us for continued growth and success."
Jog brings more than 25 years of finance experience, including roles at several public
corporations. Most recently, he served as vice president of finance for Celera Genomics
(NYSE: CRA) and Celera Diagnostics, where he was responsible for the financial functions
of these two Applera Corporation businesses. Prior to this, Jog served as vice president of
planning and corporate controller for Applera Corporation.
"XDxís broad-based technology platform has enormous potential, and Iím extremely excited
to be part of the team bringing this innovation to the industry," said Jog.
Prior to joining Applera Corporation, Jog worked as vice president and controller at
Hercules Incorporated (NYSE: HPC), a specialty chemicals provider based in Wilmington,
Del. For 13 years prior to that, he was successively with Coopers & Lybrand and Price
Waterhouse, which have since merged to become PricewaterhouseCoopers LLP.
Jog received a Bachelor of Commerce degree from Delhi University in Delhi, India, and an
MBA degree from Temple University in Philadelphia, Pa. Jog is a member of the American
Institute of Certified Public Accountants and the Financial Executives Institute.
About XDx Inc.
Founded in 2000, XDx Inc. is a molecular diagnostics company based in South San Francisco, Calif.
Setting the stage for a new era in personalized medicine, XDx is one of the first companies to
develop and commercialize practical applications built on insights from the Human Genome Project.
The company has developed a proprietary new method for noninvasively monitoring the immune
system by measuring gene expression in a patientsí peripheral blood. The technology offers the
potential to decrease healthcare costs and significantly improve the quality of life for patients with a
variety of life-threatening or life-altering, immune-mediated diseases. More information can be
found at www.xdx.com.
About AlloMapTM Molecular Expression Testing
AlloMap molecular expression testing is a noninvasive method for determining the risk of rejection
in heart transplant recipients. The test translates the complex signals of the immune systemís
multiple genes and pathways, specifically those associated with heart transplant rejection, into an
objective, actionable score. AlloMap testing enables clinicians — for the first time — to monitor the
immune system early, identifying the risk of tissue damage before it occurs, and to manage
immunosuppressive therapy proactively. The clinical value of AlloMap testing was demonstrated in a
landmark multi-center, prospective study known as Cardiac Allograft Rejection Gene Expression
Observational (CARGO). In addition, clinical trials are currently underway to determine the value of
AlloMap testing in lung transplantation. The company also plans to evaluate the utility of this
technology in autoimmune conditions such as lupus and Crohnís disease. More information can be
found at www.allomap.com.
|Tammy Reilly|| ||Kelly McKenna